BACKGROUND A reduced response to aspirin and clopidogrel predicts ischemic events, but reliable tests are needed to identify low responders. We compared 3 platelet-function tests during long-term dual treatment with aspirin and clopidogrel. METHODS Patients who underwent a percutaneous coronary intervention and were receiving a combination of 325 mg/day aspirin and 75 mg/day clopidogrel were ...

BACKGROUND Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel. The presence of CYP 2C19*2 polymorphism can reduce the formation of the active metabolite of clopidogrel, resulting in less platelet inhibition. PATIENTS AND METHODS Patients with symptomatic coronary artery disease, all on chronic single aspiri...

Platelet aggregation inhibition is mandatory for patients undergoing percutaneous coronary intervention (PCI) [1]. High on-treatment plate-let reactivity is an important independent risk factor for the occurrence of thrombotic and ischemic events after PCI [2]. Some point of care platelet aggregation assays are currently used in daily practice as a substitute for more expensive and time consumi...

OBJECTIVE Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients. RESEARCH DESIGN AND METHODS We examined the effect of aspirin (81, 162, and 325 mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpati...

AIM High on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are associated with atherothrombotic events following coronary stenting. There are, however, few data concerning high on-treatment platelet reactivity to both aspirin and clopidogrel simultaneously. The aim of the present study was to determine the incidence of dual high on-treatment platelet react...

The point-of-care platelet assay (VerifyNow® Aspirin assay) is a convenient and accurate assay used to measure baseline platelet function and to assess the platelet inhibition effect of aspirin in the nondialysis population. We evaluated the accuracy and reliability of this assay in the measurement of baseline platelet function in hemodialysis (HD) patients by assessing its precision, reproduci...

BACKGROUND An association has been reported between CYP2C19 polymorphism and the altered antiplatelet activity of clopidogrel. We investigated this association using the newly introduced platelet function analyzer (PFA)-200 (INNOVANCE PFA-200 System; Siemens Healthcare, Germany) P2Y test. METHODS Polymorphisms of CYP2C19*2, *3, *17 and the degree of inhibition of platelet function were determ...

BACKGROUND AND OBJECTIVES Residual platelet reactivity in patients who are taking clopidogrel is commonly measured with VerifyNow assay, which is based on the principle of light transmission aggregometry. However, to evaluate the residual platelet reactivity, it would be more accurate if the reactivity of platelet glycoprotein (GP) IIb/IIIa is directly monitored. In this study, PAC1, a monoclon...

Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), Verify...